PMID: 22355972Feb 24, 2012Paper

Update of old and emerging therapies in chronic hepatitis C

JPMA. the Journal of the Pakistan Medical Association
Syed Iftekhar Haider, Jameel Ahmad

Abstract

The main aim in treating hepatitis C virus (HCV) infection is to achieve a sustained virological response (SVR). It is defined as undetectable HCV-RNA in peripheral blood 24 weeks after the end of treatment. The RNA is detected by polymerase chain reaction (PCR) technique. The SVR practically reflects eradication of HCV infection and cure of the underlying HCV-induced liver disease. Treatment of HCV-induced chronic hepatitis includes one of the available Interferon-alpha (INF-alpha) in combination with Ribavirin (RBV). To achieve much better results, combination of PEG-INF with RBV is currently recommended. This regimen is quite effective in treating HCV genotype 2 and 3 but much less so in genotypes 1 and 4. At the same time it has long been observed that these combinations have sometimes severe side effects and contraindications limiting their efficacy and applicability in a significant number of chronic HCV patients. Therefore, the importance of improving existing therapies and developing new, effective, safe and tolerable drugs is well appreciated, worldwide. This review describes improvements in the current standard therapy and new emerging drugs.

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Related Papers

Journal of Viral Hepatitis
M Deutsch, S J Hadziyannis
Vojnosanitetski pregled. Military-medical and pharmaceutical review
Nada Kuljić-KapulicaRadmila Rajić
Expert Review of Gastroenterology & Hepatology
Catherine FrançoisEric Nguyen-Khac
Expert Opinion on Emerging Drugs
V SorianoPablo Barreiro
© 2022 Meta ULC. All rights reserved